Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹2143.92 Cr |
| Fresh Issue | ₹200.94 Cr |
| Offer for Sale | ₹1942.98 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹815.00-825.00 per share |
| Discount | Retail: 0.00,Employee: 40.00 |
| BSE Code | 543308 |
| NSE Code | KIMS |
| Registrar | MUFG Intime India Pvt.Ltd. |
| Lead Managers | Kotak Mahindra Capital Co.Ltd. |
| Allotment Status | |
| DRHP |
| RHP |
| Final Prospectus |
| Anchor List |
 ₹0 A/C OpeningFree MF ₹20F&O Trade ₹0Delivery 1Cr+Customers Open Free Account → |
 ₹0 A/C Opening₹0 AMC Trading Account ₹20F&O Trade ₹20Delivery FreeIPO Apply Open Free Account → |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 18 shares and in multiples thereof
Incorporated in 1973, Krishna Institute of Medical Sciences Limited (KIMS) is one of the largest healthcare groups in AP and Telangana. KIMS provides multi-disciplinary healthcare services with a key focus on primary, secondary, & tertiary care in tier 2-3 cities. The company offers a comprehensive range of healthcare services including oncology, cardiac sciences, neurosciences, gastric sciences, orthopaedics, renal sciences, organ transplantation, and mother & child care.
As of March 31, 2021, it operates through 9 multi-speciality hospitals under the brand name of "KIMS Hospitals" with an aggregate bed capacity of 3,064 under the "KIMS Hospitals" brand, with an aggregate bed capacity of 3,064 including over 2,500 operational beds.
Competitive strengths
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment/pre-payment, in full or part, of certain borrowings availedby our Companyand by ourSubsidiaries vizKHKPL, SIMSPL and KHEPL | 150.00 |
| 2 | General corporate purposes | 41.66 |
| Period Ended | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 |
|---|---|---|---|
| Assets | 1,436.15 | 1,195.89 | 1,119.71 |
| Total Income | 1,340.10 | 1,128.73 | 923.87 |
| Profit After Tax | 205.48 | 115.07 | -48.81 |
| EBITDA | 381.05 | 251.08 | 86.82 |
| NET Worth | 863.73 | 598.13 | 540.66 |
| Reserves and Surplus | 786.14 | 523.64 | 466.17 |
| Total Borrowing | 270.47 | 320.78 | 288.10 |
| Amount in ₹ Crore | |||
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fees payable to the BRLMs (including underwriting commission, brokerage and selling commission payable to members of the syndicate) | 59.70 |
| 2 | Selling commission and processing fees for SCSBs (1)(2) and Bidding Charges(3)(4)for Members of the Syndicate, Registered Brokers(5), RTAs and CDPs | 2.84 |
| 3 | Fees payable to the Registrar to the Offer | 1.03 |
| 4 | Listing fees, SEBI filing fees, book building software fees and other regulatory expenses | 6.85 |
| 5 | Printing and stationery expenses, advertising and marketing expenses for the Offer and fees payable to the legal counsels | 6.50 |
| 6 | Other Advisors to the Offer | 10.94 |
| 7 | Miscellaneous | 1.50 |
Last Updated on 17-Jul-2026 15:25:12
